Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

85.50 +2.09 (+2.50%)
Streaming Delayed Price Updated: 10:20 AM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
Breaking Down Blueprint Medicines: 14 Analysts Share Their Views
Via Benzinga
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts
Via Benzinga
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
13 Analysts Assess Blueprint Medicines: What You Need To Know
Via Benzinga
Breaking Down Blueprint Medicines: 10 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 13, 2025
Via Benzinga
Analyst Expectations For Blueprint Medicines's Future
Via Benzinga
What Analysts Are Saying About Blueprint Medicines Stock
Via Benzinga
Is NASDAQ:BPMC a Fit for high Growth Investing Strategies?
Why the high growth investor may take a look at BLUEPRINT MEDICINES CORP (NASDAQ:BPMC). 
Via Chartmill
Key Takeaways From Blueprint Medicines Analyst Ratings
Via Benzinga
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush... 
Via Benzinga
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
Via Benzinga
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities. 
Via Benzinga
Analyst Ratings For Blueprint Medicines
Via Benzinga
15 Analysts Have This To Say About Blueprint Medicines
Via Benzinga
Expert Ratings For Blueprint Medicines
Via Benzinga
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Via Benzinga
Unveiling 18 Analyst Insights On Blueprint Medicines
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Blueprint Medicines Corporation and Encourages Investors to Contact the Firm
From Schall Law
Via GlobeNewswire
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Via Benzinga
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BPMC Stock Earnings: Blueprint Medicines Beats EPS, Beats Revenue for Q1 2024
BPMC stock results show that Blueprint Medicines beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Via Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.